STOCK TITAN

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

(Positive)
Tags

iHuman (NYSE: IH) reported unaudited Q4 2025 and full-year results. Q4 revenue was RMB190.7 million (US$27.3M), down from RMB232.7 million a year earlier. FY2025 revenue was RMB807.0 million (US$115.4M), down from RMB922.2 million in 2024. Net income for FY2025 was RMB95.4 million (US$13.6M). Average total MAUs were 24.98 million for FY2025. The board approved a special cash dividend of US$0.02 per ordinary share (US$0.10 per ADS), totaling ~US$5.1 million, payable in May 2026.

Loading...
Loading translation...

Positive

  • Special dividend of US$0.10 per ADS (~US$5.1M aggregate)
  • Research & development expenses -15.9% YoY in FY2025
  • Total operating expenses -15.4% YoY in FY2025
  • Cash and short-term investments of RMB1,151.1M at year-end

Negative

  • Revenue -12.5% YoY in FY2025 (RMB922.2M to RMB807.0M)
  • Gross profit -14.5% YoY in FY2025 (RMB640.2M to RMB547.6M)
  • Deferred revenue and customer advances -22.4% YoY (RMB283.3M to RMB219.9M)

News Market Reaction – IH

+1.49%
+1.49% Session close to close

In the Mar 31 session, IH gained 1.49%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement delivered Q4 and FY2025 results showing continued profitability but declining reve...
Analysis

This announcement delivered Q4 and FY2025 results showing continued profitability but declining revenues and MAUs, alongside a special dividend of about US$5.1M. Cash and investments of RMB1,151.1M underline a solid balance sheet, while management emphasized AI-enabled products and international growth. Historically, earnings have produced modest average moves near -2.02%. Investors may watch future revenue trends, MAU stabilization, and the durability of dividends and profitability across 2026.

Key Figures

Q4 2025 revenue: RMB190.7M (US$27.3M) Q4 2025 net income: RMB15.4M (US$2.2M) Q4 2025 MAUs: 23.57M +5 more
8 metrics
Q4 2025 revenue RMB190.7M (US$27.3M) Fourth quarter 2025 vs RMB232.7M prior-year quarter
Q4 2025 net income RMB15.4M (US$2.2M) Fourth quarter 2025 vs RMB26.5M prior-year quarter
Q4 2025 MAUs 23.57M Average total MAUs vs 25.78M prior-year quarter
FY 2025 revenue RMB807.0M (US$115.4M) Fiscal year 2025 vs RMB922.2M in 2024
FY 2025 net income RMB95.4M (US$13.6M) Fiscal year 2025 vs RMB98.6M in 2024
FY 2025 MAUs 24.98M Average total MAUs vs 26.47M in fiscal year 2024
Cash & investments RMB1,151.1M (US$164.6M) Cash, cash equivalents and short-term investments at Dec 31, 2025
Special cash dividend US$0.10 per ADS; ~US$5.1M total Dividend to holders as of Apr 17, 2026; third consecutive year

Previous Earnings Reports

5 past events · Latest: Dec 29 (Neutral)
Same Type Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Dec 29 Q3 2025 earnings Neutral -0.9% Q3 2025 revenue decline but continued profitability and strong cash balance.
Sep 18 Q2 2025 earnings Neutral -3.6% Q2 2025 revenue drop offset by higher net income and cost optimization.
Jun 26 Q1 2025 earnings Neutral -3.4% Q1 2025 revenue decline with higher net income and steady MAUs.
Mar 25 Q4/FY 2024 earnings Neutral -2.3% FY2024 revenue down but MAUs up and special dividend announced.
Dec 26 Q3 2024 earnings Neutral +0.1% Q3 2024 revenue decline with record MAUs and continued profitability.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Earnings releases have typically produced modest negative moves around -2%, even when profitability was maintained.

Recent Company History

Over the past year, iHuman’s earnings updates have shown consistent profitability but recurring revenue pressure. Q4 and FY2024 results highlighted declining revenues yet ongoing dividends and AI-driven product expansion. Q1–Q3 2025 continued the theme: revenues trended down while net income stayed positive and cash remained strong, supported by new devices, content partnerships, and U.S. expansion. Today’s Q4/FY2025 release again reports lower revenues and MAUs but sustained profitability and another special dividend, extending this mixed but resilient trajectory.

Key Terms

maus, daus, ads, non-gaap financial measures, +2 more
6 terms
maus technical
"Average total MAUs[1] for the fourth quarter were 23.57 million..."
Monthly active users (often abbreviated MAUs) counts the number of distinct people who use a digital product or service at least once during a 30-day period. Investors use it like a foot-traffic counter for an online business: rising MAUs suggest growing reach and potential sales, while falling MAUs can signal weakening engagement and future revenue risk. It helps gauge how well a company attracts and retains real, repeat customers over time.
daus technical
"daily active users (DAUs) on the U.S. Apple App Store increased..."
DAUs stands for "daily active users," a count of unique people who use a digital product (app, website, or service) at least once each day. Investors watch DAUs as a simple gauge of how many real people are regularly engaging with a company's product—similar to counting daily foot traffic at a store—because steady or growing daily use often signals stronger revenue potential, customer loyalty, and the ability to monetize that audience over time.
ads financial
"US$0.02 per ordinary share, or US$0.10 per American Depositary Share (ADS)..."
Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.
non-gaap financial measures financial
"iHuman considers and uses non-GAAP financial measures, such as adjusted..."
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
share-based compensation expenses financial
"excluding share-based compensation expenses, respectively. Adjusted operating income..."
Share-based compensation expenses are the accounting costs a company records when it pays employees, directors or contractors with company stock, stock options, or other equity instruments instead of cash. Investors care because these expenses reduce reported profits and can increase the number of outstanding shares, diluting ownership — like a business paying wages with gift cards that count as payroll cost and also add more gift cards in circulation.
u.s. gaap regulatory
"presented in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP")."
U.S. GAAP is a set of rules and standards that companies in the United States follow to prepare their financial reports. It helps ensure that financial information is consistent and clear, so investors and others can compare and understand a company's financial health easily.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BEIJING, March 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. 

Fourth Quarter 2025 Highlights

  • Revenues were RMB190.7 million (US$27.3 million), compared with RMB232.7 million in the same period last year.
  • Gross profit was RMB127.5 million (US$18.2 million), compared with RMB156.4 million in the same period last year.
  • Operating income was RMB9.0 million (US$1.3 million), compared with RMB14.9 million in the same period last year.
  • Net income was RMB15.4 million (US$2.2 million), compared with RMB26.5 million in the same period last year.
  • Average total MAUs[1] for the fourth quarter were 23.57 million, compared with 25.78 million in the same period last year.

Fiscal Year 2025 Highlights

  • Revenues were RMB807.0 million (US$115.4 million), compared with RMB922.2 million in fiscal year 2024.
  • Gross profit was RMB547.6 million (US$78.3 million), compared with RMB640.2 million in fiscal year 2024.
  • Operating income was RMB66.8 million (US$9.5 million), compared with RMB71.9 million in fiscal year 2024.
  • Net income was RMB95.4 million (US$13.6 million), compared with RMB98.6 million in fiscal year 2024.
  • Average total MAUs were 24.98 million, compared with 26.47 million in fiscal year 2024.

[1] "Average total MAUs" refers to the monthly average of the sum of the MAUs of each of the Company's apps during a specific period, which is counted based on the number of unique mobile devices through which such app is accessed at least once in a given month, and duplicate access to different apps is not eliminated from the total MAUs calculation.

Dr. Peng Dai, Director and Chief Executive Officer of iHuman, commented, "During the fourth quarter, we effectively executed our key strategic initiatives, maintaining operational resilience amid a complex environment. As shifting demographic trends reshape the childhood education landscape, we have proactively evolved our product portfolio to ensure long-term sustainability.

A cornerstone of this evolution is our strategic expansion into broader user segments. In the fourth quarter, we launched FreeTalk, an AI-native oral English application designed for a broad spectrum of learners seeking to improve their spoken English across general, academic, and professional contexts. By providing on-demand access to highly realistic AI-powered digital tutors, FreeTalk effectively lowers the barriers to mastering spoken English while creating a flexible, judgment-free environment that helps mitigate speaking anxiety. At the same time, the app allows users to progress through structured learning materials at their own pace and tailor learning content to their individual needs, significantly improving learning efficiency. Powered by advanced speech recognition and generative AI, the platform helps strengthen overall English communication skills by delivering immersive, guided dialogue with real-time adaptive feedback, helping learners refine their pronunciation, fluency, grammar, and vocabulary across a wide range of real-world scenarios. The launch of FreeTalk marks a significant milestone in our strategic expansion beyond childhood education, broadening our total addressable market, extending the user lifecycle, and diversifying our long-term growth opportunities.

Alongside these initiatives, we continued to drive product innovation across our core offerings. Within iHuman Chinese, we introduced a new interactive "Animal Park" module designed around an innovative learning cycle that combines knowledge discovery with built-in review. Children can unlock different animals as they master new Chinese characters, while reinforcement is seamlessly embedded into frequent, engaging interactions such as feeding and cleaning. By integrating literacy learning with edutainment-driven progression, the module adds elements of joy and motivation that enhance engagement and reinforce learning outcomes. We also expanded our smart device portfolio with iHuman AI Bilingual Early Learning Tablet. This device offers families a secure, one-stop learning solution that integrates our comprehensive content ecosystem of stories, animations, songs, and interactive activities. In addition, the tablet features certified eye-protection capabilities and a child-friendly form factor, promoting healthy usage habits while fostering a genuine love of learning.

Our Kunpeng Animation Studio continued to make steady progress in advancing our original animation content and IP. Building on the success of the first Cosmicrew movie, we recently launched the franchise's second installment Ice Planet, further strengthening its presence among young audiences. To complement the movie's theatrical screenings, we organized a series of offline fan engagement activities, creating opportunities for children to interact directly with the characters. These in-person experiences extended engagement beyond the screen, deepening audience connection and brand affinity.

Looking into 2026, we will continue to execute with focus and discipline, advancing our product innovation, content strength, and technology to further enhance user experience and learning effectiveness. While navigating an evolving environment, we remain committed to prudent operations and long-term sustainability, with the aim of creating enduring value for users and shareholders."

Ms. Vivien Weiwei Wang, Director and Chief Financial Officer of iHuman, added, "During the quarter, we made solid progress in our international expansion with our global offerings gaining broader market recognition. Aha World, our open-ended, creativity-driven digital world designed to encourage exploration and imagination, delivered particularly strong performance. From Thanksgiving through the New Year period, daily active users (DAUs) on the U.S. Apple App Store increased by approximately 30%, highlighting the product's growing appeal in the largest overseas market and its long-term growth potential. In addition, Reading Stars, the innovative reading product we developed in collaboration with Cricket Media, has quickly gained industry recognition for its high-quality content and innovative design. The product was recently honored with both the U.S. National Parenting Product Awards (NAPPA) and the Mom's Choice Awards (MCA), demonstrating the strong endorsement of our products by the U.S. market.

Reflecting our confidence in the business and commitment to shareholder returns, our board of directors has approved a special cash dividend of US$0.02 per ordinary share, or US$0.10 per American Depositary Share (ADS), totaling approximately US$5.1 million. This marks the third consecutive year in which we have declared a special cash dividend, reflecting the structural sustainability of our financial performance.

Looking ahead, we are encouraged by our resilient business performance and believe our differentiated, content-driven portfolio positions us well to continue building our global presence and creating long-term value."

Fourth Quarter 2025 Unaudited Financial Results

Revenues

Revenues were RMB190.7 million (US$27.3 million), compared with RMB232.7 million in the same period last year. The decrease in revenues was primarily due to the decline in China's newborn population and more conservative consumer spending.

Average total MAUs for the quarter were 23.57 million, compared with 25.78 million in the same period last year. The decrease in MAUs was primarily due to the decline in China's newborn population.

Cost of Revenues

Cost of revenues was RMB63.2 million (US$9.0 million), compared with RMB76.2 million in the same period last year. The decline in cost of revenues was in line with the decrease in revenues.

Gross Profit and Gross Margin

Gross profit was RMB127.5 million (US$18.2 million), compared with RMB156.4 million in the same period last year. Gross margin was 66.9%, compared with 67.2% in the same period last year.

Operating Expenses

Total operating expenses were RMB118.5 million (US$16.9 million), a decrease of 16.3% from RMB141.5 million in the same period last year.

Research and development expenses were RMB44.9 million (US$6.4 million), a decrease of 29.0% from RMB63.3 million in the same period last year, primarily due to savings in payroll-related expenses.

Sales and marketing expenses were RMB52.7 million (US$7.5 million), compared with RMB54.1 million in the same period last year.

General and administrative expenses were RMB20.8 million (US$3.0 million), a decrease of 13.7% from RMB24.1 million in the same period last year, primarily due to savings in payroll-related and other administrative expenses.

Operating Income

Operating income was RMB9.0 million (US$1.3 million), compared with RMB14.9 million in the same period last year.

Net Income

Net income was RMB15.4 million (US$2.2 million), compared with RMB26.5 million in the same period last year.

Basic and diluted net income per ADS were RMB0.30 (US$0.04) and RMB0.29 (US$0.04), respectively, compared with RMB0.51 and RMB0.49 in the same period last year. Each ADS represents five Class A ordinary shares of the Company.

Deferred Revenue and Customer Advances

Deferred revenue and customer advances were RMB219.9 million (US$31.4 million) as of December 31, 2025, compared with RMB283.3 million as of December 31, 2024.

Cash, Cash Equivalents and Short-term Investments

Cash, cash equivalents and short-term investments were RMB1,151.1 million (US$164.6 million) as of December 31, 2025, compared with RMB1,168.7 million as of December 31, 2024.

Fiscal Year 2025 Unaudited Financial Results

Revenues

Revenues were RMB807.0 million (US$115.4 million), compared with RMB922.2 million in fiscal year 2024. The decrease in revenues was primarily due to the decline in China's newborn population and more conservative consumer spending.

Average total MAUs were 24.98 million, compared with 26.47 million in fiscal year 2024. The decrease in MAUs was primarily due to the decline in China's newborn population.

Cost of Revenues

Cost of revenues was RMB259.4 million (US$37.1 million), compared with RMB282.0 million in fiscal year 2024. The decline in cost of revenues was in line with the decrease in revenues.

Gross Profit and Gross Margin

Gross profit was RMB547.6 million (US$78.3 million), compared with RMB640.2 million in fiscal year 2024. Gross margin was 67.9%, compared with 69.4% in fiscal year 2024. The decrease in gross margin was mainly due to the diversification and structural upgrades of the Company's product portfolio.

Operating Expenses

Total operating expenses were RMB480.9 million (US$68.8 million), a decrease of 15.4% from RMB568.2 million in fiscal year 2024.

Research and development expenses were RMB208.4 million (US$29.8 million), a decrease of 15.9% from RMB247.8 million in fiscal year 2024, primarily due to savings in payroll-related expenses.

Sales and marketing expenses were RMB181.0 million (US$25.9 million), a decrease of 18.2% from RMB221.2 million in fiscal year 2024, primarily due to cost savings in marketing activities.

General and administrative expenses were RMB91.4 million (US$13.1 million), a decrease of 7.9% from RMB99.3 million in fiscal year 2024, primarily due to savings in payroll-related and other administrative expenses.

Operating Income

Operating income was RMB66.8 million (US$9.5 million), compared with RMB71.9 million in fiscal year 2024.

Net Income

Net income was RMB95.4 million (US$13.6 million), compared with RMB98.6 million in fiscal year 2024.

Basic and diluted net income per ADS were RMB1.86 (US$0.27) and RMB1.78 (US$0.25), respectively, compared with RMB1.88 and RMB1.82 in fiscal year 2024. Each ADS represents five Class A ordinary shares of the Company.

Special Cash Dividend

To deliver return of capital to shareholders, the Company's board of directors (the "Board") approved a special cash dividend of US$0.02 per ordinary share, or US$0.10 per ADS, to holders of ordinary shares and holders of ADSs as of the close of business on April 17, 2026 New York Time, payable in U.S. dollars. The aggregate amount of the special dividend will be approximately US$5.1 million. The payment date is expected to be on or around May 8, 2026 and May 15, 2026 for holders of ordinary shares and holders of ADSs, respectively.

Exchange Rate Information

The U.S. dollar (US$) amounts disclosed in this press release, except for those transaction amounts that were actually settled in U.S. dollars, are presented solely for the convenience of the reader. The conversion of Renminbi (RMB) into US$ in this press release is based on the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of December 31, 2025, which was RMB6.9931 to US$1.00. The percentages stated in this press release are calculated based on the RMB amounts.

Non-GAAP Financial Measures

iHuman considers and uses non-GAAP financial measures, such as adjusted operating income, adjusted net income and adjusted diluted net income per ADS, as supplemental metrics in reviewing and assessing its operating performance and formulating its business plan. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). iHuman defines adjusted operating income, adjusted net income and adjusted diluted net income per ADS as operating income, net income and diluted net income per ADS excluding share-based compensation expenses, respectively. Adjusted operating income, adjusted net income and adjusted diluted net income per ADS enable iHuman's management to assess its operating results without considering the impact of share-based compensation expenses, which are non-cash charges. iHuman believes that these non-GAAP financial measures provide useful information to investors in understanding and evaluating the Company's current operating performance and prospects in the same manner as management does, if they so choose.

Non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools, which possibly do not reflect all items of expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of the non-GAAP financial measures. In addition, the non-GAAP financial measures iHuman uses may differ from the non-GAAP measures used by other companies, including peer companies, and therefore their comparability may be limited. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with GAAP.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about iHuman's beliefs and expectations, are forward-looking statements. Among other things, the description of the management's quotations in this announcement contains forward-looking statements. iHuman may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: iHuman's growth strategies; its future business development, financial condition and results of operations; its ability to continue to attract and retain users, convert non-paying users into paying users and increase the spending of paying users, the trends in, and size of, the market in which iHuman operates; its expectations regarding demand for, and market acceptance of, its products and services; its expectations regarding its relationships with business partners; general economic and business conditions; regulatory environment; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in iHuman's filings with the SEC. All information provided in this press release is as of the date of this press release, and iHuman does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About iHuman Inc.

iHuman Inc. is a leading provider of tech-powered, intellectual development products in China that is committed to making the child-upbringing experience easier for parents and transforming intellectual development into a fun journey for children. Benefiting from a deep legacy that combines nearly three decades of experience in the parenthood industry, superior original content, advanced high-tech innovation DNA and research & development capabilities with cutting-edge technologies, iHuman empowers parents with tools to make the child-upbringing experience more efficient. iHuman's unique, fun and interactive product offerings stimulate children's natural curiosity and exploration. The Company's comprehensive suite of innovative and high-quality products include self-directed apps, interactive content and smart devices that cover a broad variety of areas to develop children's abilities in speaking, critical thinking, independent reading and creativity. Leveraging advanced technological capabilities, including 3D engines, AI/AR functionality, and big data analysis on children's behavior & psychology, iHuman believes it will continue to provide superior experience that is efficient and relieving for parents, and effective and fun for children, in China and all over the world, through its integrated suite of tech-powered, intellectual development products.

For more information about iHuman, please visit: https://ir.ihuman.com/

For investor and media enquiries, please contact:

iHuman Inc.
Mr. Justin Zhang
Investor Relations Director
Phone: +86-10-5780-6606
E-mail: ir@ihuman.com

Christensen Advisory
Ms. Alice Li
Phone: +86-10-5900-1548
E-mail: ihumangroup@christensencomms.com

 

 

 

iHuman Inc.


UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

except for number of shares, ADSs, per share and per ADS data)



December 31,


December 31,


December 31,


2024


2025


2025


RMB


RMB


US$







ASSETS






Current assets






Cash and cash equivalents 

1,123,292


1,151,120


164,608

Short-term investments

45,457


-


-

Accounts receivable, net

52,030


47,070


6,731

Inventories, net

23,475


21,388


3,058

Amounts due from related parties

2,051


4,314


617

Prepayments and other current assets

89,512


74,483


10,651

Total current assets

1,335,817


1,298,375


185,665

Non-current assets






Property and equipment, net

3,476


2,563


367

Intangible assets, net

16,429


17,634


2,522

Operating lease right-of-use assets

14,885


11,586


1,657

Long-term investment

26,333


26,333


3,766

Other non-current assets

22,701


11,864


1,696

Total non-current assets

83,824


69,980


10,008

Total assets

1,419,641


1,368,355


195,673







LIABILITIES






Current liabilities






Accounts payable

30,233


25,083


3,587

Deferred revenue and customer advances

283,251


219,913


31,447

Amounts due to related parties

1,734


1,066


152

Accrued expenses and other current liabilities

126,501


115,749


16,552

Dividend payable

2,164


-


-

Current operating lease liabilities

3,661


2,166


310

Total current liabilities

447,544


363,977


52,048

Non-current liabilities






Non-current operating lease liabilities

11,252


9,208


1,317

Total non-current liabilities

11,252


9,208


1,317

Total liabilities

458,796


373,185


53,365

SHAREHOLDERS' EQUITY






Ordinary shares (par value of US$0.0001 per share,

     700,000,000 Class A shares authorized as of

     December 31, 2024 and December 31, 2025;

     125,122,382 Class A shares issued and 116,084,207

     outstanding as of December 31, 2024; 125,122,382

     Class A shares issued and 111,541,887 outstanding as

     of December 31, 2025; 200,000,000 Class B shares

     authorized, 144,000,000 Class B ordinary shares

     issued and outstanding as of December 31, 2024 and

     December 31, 2025; 100,000,000 shares

     (undesignated) authorized, nil shares (undesignated)

     issued and outstanding as of December 31, 2024 and

     December 31, 2025)

185


186


27

Additional paid-in capital

996,657


960,641


137,370

Treasury stock

(26,296)


(43,483)


(6,218)

Statutory reserves

8,395


8,463


1,210

Accumulated other comprehensive income

24,009


16,134


2,307

Retained earnings (accumulated deficit)

(42,105)


53,229


7,612

Total shareholders' equity

960,845


995,170


142,308

Total liabilities and shareholders' equity

1,419,641


1,368,355


195,673

 

 

iHuman Inc.


UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

except for number of shares, ADSs, per share and per ADS data)



For the three months ended


For the year ended


December 31,


September 30,


December 31,


December 31,


December 31,


December 31,


December 31,


2024


2025


2025


2025


2024


2025


2025


RMB


RMB


RMB


US$


RMB


RMB


US$















Revenues

232,684


205,764


190,654


27,263


922,201


807,019


115,402

Cost of revenues

(76,243)


(65,134)


(63,198)


(9,037)


(282,048)


(259,409)


(37,095)















Gross profit

156,441


140,630


127,456


18,226


640,153


547,610


78,307















Operating expenses














Research and development expenses

(63,308)


(55,294)


(44,930)


(6,425)


(247,757)


(208,443)


(29,807)

Sales and marketing expenses

(54,109)


(45,720)


(52,715)


(7,538)


(221,230)


(180,969)


(25,878)

General and administrative expenses

(24,106)


(22,949)


(20,808)


(2,976)


(99,254)


(91,442)


(13,076)

Total operating expenses

(141,523)


(123,963)


(118,453)


(16,939)


(568,241)


(480,854)


(68,761)

Operating income

14,918


16,667


9,003


1,287


71,912


66,756


9,546

Other income, net

12,245


5,318


6,941


993


38,689


35,033


5,010

Income before income taxes

27,163


21,985


15,944


2,280


110,601


101,789


14,556

Income tax expenses

(682)


(400)


(534)


(76)


(12,012)


(6,387)


(913)

Net income

26,481


21,585


15,410


2,204


98,589


95,402


13,643















Net income per ADS:














   - Basic

0.51


0.42


0.30


0.04


1.88


1.86


0.27

   - Diluted

0.49


0.40


0.29


0.04


1.82


1.78


0.25















Weighted average number of ADSs:














   - Basic

52,097,127


51,201,957


51,105,266


51,105,266


52,400,383


51,395,037


51,395,037

   - Diluted

53,965,183


53,434,919


53,305,240


53,305,240


54,239,751


53,522,994


53,522,994















Total share-based compensation expenses included in:














Cost of revenues

18


8


6


1


106


31


4

Research and development expenses

273


87


98


14


1,303


362


52

Sales and marketing expenses

34


16


14


2


164


62


9

General and administrative expenses

229


85


83


12


1,251


267


38

 

 

iHuman Inc.


UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS


(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

except for number of shares, ADSs, per share and per ADS data)



For the three months ended


For the year ended


December 31,


September 30,


December 31,


December 31,


December 31,


December 31,


December 31,


2024


2025


2025


2025


2024


2025


2025


RMB


RMB


RMB


US$


RMB


RMB


US$















Operating income

14,918


16,667


9,003


1,287


71,912


66,756


9,546

Share-based compensation expenses

554


196


201


29


2,824


722


103

Adjusted operating income

15,472


16,863


9,204


1,316


74,736


67,478


9,649















Net income

26,481


21,585


15,410


2,204


98,589


95,402


13,643

Share-based compensation expenses

554


196


201


29


2,824


722


103

Adjusted net income

27,035


21,781


15,611


2,233


101,413


96,124


13,746















Diluted net income per ADS

0.49


0.40


0.29


0.04


1.82


1.78


0.25

Impact of non-GAAP adjustments

0.01


0.01


0.00


0.00


0.05


0.02


0.01

Adjusted diluted net income per ADS

0.50


0.41


0.29


0.04


1.87


1.80


0.26















Weighted average number of ADSs – diluted

53,965,183


53,434,919


53,305,240


53,305,240


54,239,751


53,522,994


53,522,994

Weighted average number of ADSs – adjusted

53,965,183


53,434,919


53,305,240


53,305,240


54,239,751


53,522,994


53,522,994

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ihuman-inc-announces-fourth-quarter-and-fiscal-year-2025-unaudited-financial-results-302729823.html

SOURCE iHuman Inc.

FAQ

What were iHuman's Q4 2025 results and how did revenue change (NYSE: IH)?

Q4 2025 revenue was RMB190.7 million (US$27.3M), down year‑over‑year. According to the company, Q4 revenue declined from RMB232.7 million a year earlier, driven by demographic headwinds and more conservative consumer spending.

How did iHuman perform for fiscal year 2025 and what was FY net income (IH)?

FY2025 revenue was RMB807.0 million with net income of RMB95.4 million. According to the company, FY revenue decreased from RMB922.2 million in 2024, while net income modestly declined versus the prior year.

Did iHuman declare a dividend and what are the payment details (NYSE: IH)?

Yes. The board approved a special cash dividend of US$0.02 per ordinary share (US$0.10 per ADS). According to the company, the aggregate dividend is approximately US$5.1 million, payable in May 2026 to holders of record April 17, 2026.

How did iHuman's operating expenses and R&D change in FY2025 (IH)?

Total operating expenses fell 15.4% and R&D expenses fell 15.9% year‑over‑year in FY2025. According to the company, reductions were mainly due to payroll-related savings and cost control measures.

What happened to iHuman's deferred revenue and customer advances at year‑end 2025 (NYSE: IH)?

Deferred revenue and customer advances were RMB219.9 million as of December 31, 2025. According to the company, this represents a decrease from RMB283.3 million a year earlier, reflecting lower advance sales activity.

How many average monthly active users did iHuman report for FY2025 (IH)?

Average total MAUs for FY2025 were 24.98 million. According to the company, this declined from 26.47 million in FY2024, primarily attributed to a decrease in China's newborn population.